Veracyte, Inc. 2026 Q2 - Results - Earnings Call Presentation
Veracyte Inc VCYT
$46.32
▼ -22.52%
($-13.46)
⬇️ Below Yest. Low
Open
$48.77
Prev Close
$59.78
Day Range
$43.52 – $50.17
52W Range
$22.92 – $60.91
Market Cap
$3.70B
P/E (TTM)
41.34
Beta
1.96
EPS (TTM)
$1.08
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2013-10-30 |
| Shares Out. | 79,790,000 |
| Website | veracyte.com/ ↗ |
| Phone | 13026587581 |
| Employees | 755 |
| Revenue | $139.1M |
| Gross Profit | $101.2M |
| Net Income | $28.7M |
| Free Cash Flow | $155.3M |
| Total Assets | $1.44B |
| Total Liabilities | $92.0M |
| Equity | $1.34B |
About Veracyte Inc
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
Veracyte Inc is a publicly traded company under the ticker symbol VCYT on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
18 analysts (2026-07-01)
📰 Latest News for VCYT
Apple, Stryker, Coinbase And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
Needham Maintains Buy on Veracyte, Raises Price Target to $69
Veracyte, Inc. (VCYT) Q2 2026 Earnings Call Transcript
Veracyte (NASDAQ:VCYT) Smashes Q2 Estimates but Full-Year Guidance Disappoints, Shares Fall
Veracyte Raises FY2026 Sales Guidance from $582.000M-$592.000M to $590.000M-$596.000M vs $586.445M Est
Veracyte Inc (NASDAQ:VCYT) Shows a High Growth Momentum Breakout Setup Near Resistance
Veracyte Inc (NASDAQ:VCYT): A High Growth Stock With a Strong Technical Breakout Setup